Related Experiment Video
Updated: Aug 8, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Gene therapy for glioblastoma
Manish Aghi1, E Antonio Chiocca
1Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. maghi@partners.org
Abstract:
Established treatments such as surgery, radiation, and chemotherapy have only minimally altered the median survival time of patients with glioblastoma multiforme, the most common malignant brain tumor. These failures reflect the highly invasive nature of the disease, as well as the fact that few cells are actively dividing at any given time. As a result, therapies need to act in areas of the brain that are spatially separated from the site of tumor origin and over extended periods of time temporally separated from their introduction. Over the past decade, laboratory studies and early clinical trials have raised the hope that these therapeutic requirements may be fulfilled by gene therapy in which nonreplicating transgene-bearing viruses, oncolytic viruses, or migratory stem cells are used to deliver tumoricidal transgenes. The authors review the principles behind these approaches and their initial results.
Insights
Gene therapy offers new hope for glioblastoma multiforme (GBM) patients. Novel approaches using viruses or stem cells show promise for treating this aggressive brain cancer more effectively.
Area of Science:
- Neuro-oncology
- Molecular biology
- Biomedical engineering
Background:
- Glioblastoma multiforme (GBM) is the most common malignant brain tumor.
- Conventional treatments like surgery, radiation, and chemotherapy offer limited survival benefits for GBM patients.
- The invasive nature and slow cell division rate of GBM pose significant challenges for existing therapies.
Purpose of the Study:
- To review the principles and initial results of gene therapy for glioblastoma multiforme.
- To explore the potential of novel therapeutic strategies to overcome treatment limitations.
Main Methods:
- Review of laboratory studies and early clinical trials on gene therapy for GBM.
- Focus on viral vectors (nonreplicating and oncolytic viruses) and migratory stem cells for gene delivery.
- Analysis of transgene delivery and tumoricidal effects.
Main Results:
- Gene therapy approaches demonstrate potential to address spatial and temporal challenges in GBM treatment.
- Nonreplicating viruses, oncolytic viruses, and stem cells are being investigated for delivering tumoricidal transgenes.
- Early results suggest these novel methods may improve therapeutic outcomes.
Conclusions:
- Gene therapy holds significant promise for improving glioblastoma multiforme treatment.
- Viral and stem cell-based gene delivery systems represent a hopeful future direction for neuro-oncology.
- Further research and clinical trials are warranted to optimize these gene therapy strategies.
More Related Videos
Related Concept Videos
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...